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Background: Early prediction of disease severity in acute pancreatitis (AP) is crucial. The aim of this
study was to investigate the body-mass index (BMI), plasma leptin, nesfatin-1 and ghrelin levels as
potential markers predicting peripancreatic necrosis and severity in acute pancreatitis. Methods: In the
study period, 97 consecutive patients with AP were prospectively analysed. Severe AP was deﬁned ac-
cording to the Atlanta Criteria. BMI was also calculated. To measure plasma Leptin, Nesfatin-1 and
Ghrelin concentrations, the blood samples were obtained from patients within 24 hours of admission.
Results: Out of 97 patients, 92(70 females, 22 males) were considered eligible for analysis. Of the 92
patients, 30 patients (32.6%) were assessed as severe pancreatitis. BMI and leptin levels were signiﬁ-
cantly higher in patients with severe pancreatitis. The pooled sensitivity and speciﬁcity of BMI as a
predictor for the development of pancreatic necrosis were 0.90(95%CI ¼ 0.56e0.99) and 0.70(95%
CI ¼ 0.58e0.79), respectively; with an overall area under curve value of 0.78.The pooled sensitivity and
speciﬁcity of leptin levels as a predictor for development of pancreatic necrosis were 1(95%CI ¼ 0.69e1)
and 0.73(95%CI ¼ 0.62e0.82),respectively; with an overall area under curve value of 0.82.Nesfatin-1 and
ghrelin levels showed no signiﬁcant difference in patients with mild pancreatitis (6.97 ± 0.84 ng/ml and
2.3(1.0e9.9);respectively) and severe pancreatitis (6.74 ± 0.65 ng/ml and 2.0(1.9e9.9); respectively)
(p ¼ 0.1923 and 0.8531;respectively). Conclusion: BMI and plasma leptin levels both were correlated
with the severity of pancreatitis. Leptin levels showed better area under the curve, sensitivity and
speciﬁcity values compared to BMI in prediction of pancreatic necrosis.Nesfatin-1 and ghrelin levels were
not found to be predictors of the severity of disease.
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Acute pancreatitis (AP) is a common emergency with a wide
spectrum of severity. While 70e80% of patients with acute.
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(approximately 20e30%), have a severe and fatal clinical picture.
Because accurate and timely selection of patients who need
intensive care will provide a beneﬁt in reducing mortality, early
detection of potentially severe acute pancreatitis is important. In
addition to several scoring systems, a variety of cytokines, immune
response markers, proenzymes and enzyme complexes have been
used in many studies to determine the severity of pancreatitis [1].
Ranson and Acute Physiology and Chronic Health Evaluation
(APACHE II) scoring systems are the best known and most widely
used clinical criteria. Ranson criteria is used as a speciﬁc scoring
system for acute pancreatitis, and is based on several physiological
variables on admission and the 48th hour of the attack. A more
accurate but complex scoring system, the APACHE II system, allows
for monitoring of disease progression and response to therapy from
the time of admission with an interval of 24 h. However, because it
necessitates many parameters, the calculation is time-consuming
[2,3]. Therefore, researchers have been working on simple and
convenient alternative scores or single predictors. Because of the
number of available scoring systems, the Atlanta Classiﬁcation of
Severe Acute Pancreatitis has recently become widely used to
deﬁne severe acute pancreatitis when comparing some scores or
other predictors, which has helped standardization of clinical
research trials [4,5].
In recent years, many studies have emphasized that obesity is
associated with the severity of acute pancreatitis. Similar to leptin,
an adipokine synthesized from adipose tissue, ghrelin is also a
hormone that affects endocrine and exocrine functions of the
pancreas and plays a role in the regulation of energy metabolism.
There are few studies examining the association of ghrelin and
leptin levels with severity of acute pancreatitis [6,7]. However,
there are no studies on the role of nesfatin-1, another peptide
hormone that is involved in the regulation of appetite, in patients
with acute pancreatitis.
Although there are a large number of criteria to determine the
severity of acute pancreatitis, there is no consensus on a criterion.
Research is ongoing to determine the most useful criterion. In this
study, we aimed to investigate the relationship between the body-
mass index (BMI), plasma leptin, nesfatin-1 and ghrelin levels with
the severity of acute pancreatitis and peripancreatic necrosis.Table 1
Various demographic data of the patients.
Mild pancreatitis Severe pancreatitis p
Sex (Male/Female) 16/46 6/24 0.7253
Age (mean ± SD) 51.8 ± 18.3 53.9 ± 22.3 0.6230
BMI (kg/m2) 24.34 ± 3.52 29.67 ± 4.16 <0.00012. Methods
From June 2010 to July 2013, 97 consecutive patients with acute
pancreatitis who were admitted to the Department of Surgery,
University Hospital of Dicle University, were prospectively ana-
lysed. A total of 92 (70 females, 22 males) patients were included in
the study. The study was conducted after approval by the Dicle
University School of Medicine Ethics Committee and supported by
the Dicle University Research Project. The written informed con-
sents of all patients were obtained. The diagnosis of AP was made
on admittance in the emergency department based on a history of
acute abdominal pain with a 3-fold increase of serum amylase ac-
tivity. Written informed consent was obtained from all patients
before taking blood samples. The diagnosis of pancreatic necrosis
was made by contrast-enhanced computed tomography (CT)
scanning together with pancreatic ultrasonography. Severe acute
pancreatitis was deﬁned according to the criteria of Atlanta [4].
General exclusion criteria were deﬁned as 1) A time interval be-
tween onset of typical abdominal symptoms and study inclusion of
more than 48 h, 2) Presence of tumor of the pancreas or other or-
gans 3) Presence of diabetes mellitus. Obesity was evaluated by
BMI, which was calculated as weight (kilograms) divided by height
(meters) squared (kg/m2).2.1. Leptin, nesfatin-1 and ghrelin measurement
To measure plasma Leptin, Nesfatin-1 and Ghrelin concentra-
tions, the blood samples were obtained frompatients within 24 h of
admission. The collected blood samples were immediately centri-
fuged and then the separated plasma was frozen at 70 C for sub-
sequent analysis. After reaching the targetednumberof patients, the
plasma of the patients was thawed and the Nesfatin-1 (Uscn Life
Science, Wuhan, China), Ghrelin (RayBio, Norcross, GA, USA) and
Leptin (DRG Diagnostics, Marburg, Germany) concentrations were
measured by a laboratory assistant, who was blinded to the classi-
ﬁcation of the patients. Plasma Leptin, Nesfatin-1 and Ghrelin con-
centrations are expressed as nanograms per milliliter (ng/mL).
2.2. Statistical analysis
Statistical analysis was performed using Medcalc Statistical
Software (version 9.4.2). Categorical data were evaluated with the
Chi-square test and continuous variables with the Student t-test or
ManneWhitney U-test, after checking for normality using the
KolmogoroveSmirnov test. To evaluate leptin and BMI as a pre-
dictor of severe AP, receiver operating characteristic (ROC) curves
were used. Relationships between serum leptin and BMI were
assessed by simple linear regression analysis. P < 0.05 was
considered as signiﬁcant.
3. Results
Out of 97 patients, 92 were eligible for the analysis. Among the
eliminated ﬁve patients, two did not wish to participate in the
study, and the other 3 met the exclusion criteria. Of the eligible 92
patients, 70 were female (76.1%) and the mean age was 52.5 ± 19.6
(range: 17e103 years) years old (Table 1). The most common cause
of acute pancreatitis was gallstone (n ¼ 76; 82.6%). Of the other 16
cases, 6 cases were due to idiopathic causes, 4 due to alcohol intake,
3 from hyperlipidemia and 3 caused by endoscopic retrograde
cholangiopancreatography (ERCP). The main characteristics of pa-
tients are given in Table 1. Among the 92 patients, 62 patients
(67.4%) were assessed as mild pancreatitis and 30 patients (32.6%)
were assessed as severe pancreatitis. Pancreatic necrosis was
detected in 10 patients with severe pancreatitis. Plasma leptin,
nesfatin-1 and ghrelin levels in patients with mild and severe
pancreatitis are given in Table 2.
3.1. BMI
BMI was signiﬁcantly higher in patients with severe pancreatitis
(p < 0.0001) (Table 1). The pooled sensitivity and speciﬁcity of BMI
as a predictor for the development of pancreatic necrosis were 0.90
(95%CI ¼ 0.56e0.99) and 0.70 (95%CI ¼ 0.58e0.79), respectively,
with an overall area under curve (AUC) value of 0.78 using a cut-off
value greater than 26 kg/m2.
3.2. Leptin
Plasma leptin levels were signiﬁcantly higher in patients with
severe pancreatitis compared to patients with mild pancreatitis
Table 2
Plasma leptin, nesfatin-1, and ghrelin levels in mild and severe pancreatitis patients.
Mild AP Severe AP p
Leptin (ng/ml) 4.69 ± 3.46 9.32 ± 5.80 0.0002
Nesfatin-1 (ng/ml) 6.97 ± 0.84 6.74 ± 0.65 0.1923
Ghrelin (ng/ml) 2.3 (1.0e9.9) 2.0 (1.9e9.9) 0.8531
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(mean 10.0; 7.7e18.2) were signiﬁcantly higher compared to the
patients without necrosis (mean 3.4; 0.8e17.8) (p ¼ 0.0012).
The pooled sensitivity and speciﬁcity of plasma leptin levels as a
predictor for the development of pancreatic necrosis were 1 (95%
CI ¼ 0.69e1) and 0.73 (95%CI ¼ 0.62e0.82), respectively, with an
overall AUC value of 0.82 using a cut-off value greater than 7.5 ng/
mL (Fig. 1).
3.3. Nesfatin-1
Although plasma nesfatin-1 levels in patients with severe
pancreatitis were higher than patients with mild pancreatitis, there
was no statistically signiﬁcant difference (Table 2). Similarly, no
signiﬁcant difference was found in nesfatin-1 levels between pa-
tients with pancreatic necrosis (median 7.0; 5.2e8.6 ng/mL) and
patients without necrosis (median 6.9; 5.8e7.5) (p ¼ 0.5805).
3.4. Ghrelin
Although plasma ghrelin levels in patients with mild pancrea-
titis were slightly higher than patients with severe pancreatitis, the
difference was not statistically signiﬁcant (Table 2). Similarly, no
signiﬁcant difference was observed between ghrelin levels in pa-
tients with pancreatic necrosis (median 2.0, 2.0e9.0 ng/mL) and
ghrelin levels in patients without necrosis (median 2.2, 1.0e9.0),
(p ¼ 0.5805).
4. Discussion
APmanifests with different clinical outcomes ranging frommild
uncomplicated disease to a life-threatening severe disease. While
some patients may require a short hospitalization, others may be
critically ill because of multiple organ dysfunction and require
intensive care monitoring. Therefore, the early detection of theFig. 1. Receiver operating characteristic (ROC) curves of plasma leptin levels.severity of disease is important. The scoring systems used for this
purpose are complex and increase the cost and workload [2e4].
Therefore, a search for the best parameters for the estimation of
prognosis in patients with pancreatitis continues. Many predictors
are used for this purpose [6,7].
Several studies have shown that obesity is a good predictor of
prognosis in AP. The mechanism by which obesity inﬂuences the
severity of AP is still unclear. Some authors suggest that obesity
leads to aggravation of local complications within the pancreas and
peripancreatic tissue and injuries in remote organs [8]. In our study,
patients with severe pancreatitis had signiﬁcantly higher BMI than
patients with mild pancreatitis.
In recent years, several studies have been published that
investigated the role of fat-derived adipokines in the severity of AP
with some conﬂicting results. One of the most widely studied
adipokines is leptin. Konturak et al. [9], who ﬁrst examined the
relationship between leptin and AP, reported that plasma leptin
levels in patients with AP were signiﬁcantly higher than the control
group. Tukiainen et al. [10] conducted a study of 12 patients with
severe pancreatitis and 12 patients with mild pancreatitis and re-
ported that there was no relationship between plasma leptin levels
with the severity of pancreatitis. Duarte-Rojo et al. [11], although
they did not observe the role of serum leptin levels in systemic
inﬂammatory response, reported that leptin levels tend to increase
in severe pancreatitis patients. In contrast, in an experimental
pancreatitis model, Kerem et al. [6] reported that rats with severe
pancreatitis had higher leptin levels than rats with mild pancrea-
titis beginning from the 12th hour. Again Sch€afﬂer et al. [12] sug-
gested that leptin and resistin levels might be new potential
markers for severity of pancreatitis and extrapancreatic necrosis in
their study of 23 patients with AP. Our study is the most extensive
prospective study on leptin levels in AP, and patients with severe
pancreatitis and pancreatic necrosis were found to have statistically
higher plasma leptin levels than others. Moreover leptin was found
to be a predictive factor for peripancreatic necrosis with 100%
sensitivity and 73.2% speciﬁcity with a cut-off value of 7.5 ng/mL.
Leptin levels showed better area under the ROC curve, sensitivity
and speciﬁcity values compared to BMI. Christos et all [13] showed
an independent positive association between circulating levels of
leptin and sTNFa-R55 and hypothesized that activation of the TNFa
system may exert a signiﬁcant inﬂuence over leptin levels in
humans. The independent positive association of leptin levels and
pancreatic necrosis in our study might reﬂect a direct effect of the
increased cytokine expression in severe pancreatitis that stimulates
leptin gene expression.
Nesfatin-1, an 82 amino acid NUCB2 peptide structure hormone,
was ﬁrst isolated from the hypothalamus of rats [14]. Gonzalez et al.
[15] isolated abundant NUCB2 mRNA from pancreatic beta-cells. Su
et al. [16] found that injection of nesfatin-1 signiﬁcantly reduced
blood glucose levels in hyperglycemic rats. We did not ﬁnd any
study on nesfatin-1 levels in patients with pancreatitis in the
literature review. In our study, the plasma nesfatin-1 level was
found to be associated with severity of pancreatitis and pancreatic
necrosis.
There are few studies on ghrelin levels in AP in the literature. Liu
et al. [17] reported that ghrelin levels in patients with pancreatitis
were signiﬁcantly higher on admission than the levels in remission.
In the experimental study carried out by Kerem et al. [6], serum
ghrelin levels began to rise after the 12th hour and were signiﬁ-
cantly higher in patients with severe pancreatitis than patients
with mild pancreatitis. Lee et al. [18] in their study of 53 patients
reported that patients who are in the risk group for severe disease
had signiﬁcantly higher serum ghrelin levels. In our study, ghrelin
levels in the ﬁrst 24 h in patients withmild pancreatitis were higher
than patients with severe pancreatitis, but therewas no statistically
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pancreatic necrosis were similar with patients without necrosis.
A major limitation to our study was the relatively small sample
size of the patients with pancreatic necrosis. While 92 patients
were enrolled, only 10 had pancreatic necrosis. Therefore, further
studies with a greater number of patients with pancreatic necrosis
should be performed.
In conclusion, we suggest that BMI and plasma leptin levels on
admission may be used as a predictive marker for pancreatic ne-
crosis in patients with AP. Plasma nesfatin-1 and ghrelin levels did
not found signiﬁcant in severity of the disease.
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